Cardiol Therapeutics Inc. Class A CRDL 深 沪
等待开盘 05-21 09:30:00 美东时间
1.30
+0.040
+3.17%
华盛通- 最 高1.305
- 今 开1.27
- 成交量 25.88万股
- 最 低 1.265
- 昨 收 1.26
- 总市值 14.99万
- 52周最高 1.71
- 市盈率 静 --
- 换手率 0.22%
- 52周最低 0.88
- 委 比 48.90%
- 总股本 0.00亿
- 历史最高 4.96
- 量 比 0.59
- 振 幅 3.17%
- 历史最低 0.45
- 每 手 1
- 风险率 0.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cardiol Advances Key Studies and Secures Funding to Push New Heart Treatments Forward
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease,
04-01 19:32
Cardiol Therapeutics Announces Publication Of Results From Phase II ARCHER Study In ESC Heart Failure, Journal Of European Society Of Cardiology
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease,
02-10 20:30
Cardiol Therapeutics Surpasses 50% Participant Enrollment In MAVERIC Phase III Study Of CardiolRx
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease,
01-13 20:31
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
2025-12-02 09:50
Cardiol Therapeutics Announces New, Comprehensive Data From ARCHER, Randomized Double-Blind, Placebo-Controlled, Multi-Center Phase II Clinical Trial Of CardiolRx In Patients With Acute Myocarditis
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute
2025-12-01 20:32
Cardiol Therapeutics Q3 EPS $(0.09), Inline
Cardiol Therapeutics (NASDAQ:CRDL) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 30.77 percent increase over losses of $(0.13) per share from the same period last
2025-11-14 06:35
Cardiol Therapeutics Receives USPTO Notice Of Allowance For Patent On Cannabidiol Heart Therapies
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property
2025-11-13 20:49
Cardiol Therapeutics Secures $11M Financing, Advances Heart Disease Therapies
The latest announcement is out from Cardiol Therapeutics ( ($TSE:CRDL) ). Cardi...
2025-10-18 05:06
Cardiol Therapeutics to Present at Canaccord Genuity Conference
Cardiol Therapeutics ( ($TSE:CRDL) ) has shared an announcement. Cardiol Therap...
2025-08-11 20:14
Cardiol Therapeutics Reports Compelling ARCHER Trial Results Supporting Advancement of CardiolRx And CRD-38 in Myocarditis And Heart Failure
Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo.Reduction in ECV was associated with improvements
2025-08-06 19:29
